Harter, P. and Mahner, S. and Hilpert, F. and Runnebaum, I. and Ortmann, O. and Mustea, A. and Sehouli, J. and du Bois, A. and Wagner, U. (2013) Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer. GEBURTSHILFE UND FRAUENHEILKUNDE, 73 (3). pp. 221-223. ISSN 0016-5751, 1438-8804
Full text not available from this repository. (Request a copy)Abstract
HIPEC is offered to patients with ovarian, fallopian tube or primary peritoneal cancer at some hospitals. Altogether, there is still no evidence that HIPEC leads to an improvement of prognosis in any gynecologic tumor, neither in primary therapy nor in treatment of relapse. The available data indicate an increased complication rate which might negatively impact the benefit-risk balance of this procedure. In addition, standard treatment with proven efficacy might be withheld due to application of unproven methods. The use of HIPEC outside of well designed, prospective and controlled clinical trials is therefore disregarded.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | PERITONEAL CARCINOMATOSIS; CYTOREDUCTIVE SURGERY; SYSTEMIC CHEMOTHERAPY; EXPLORATORY ANALYSIS; RANDOMIZED-TRIAL; CISPLATIN; PLATINUM; DNA; MANAGEMENT; ovarian cancer; statement; HIPEC; AGO |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Frauenheilkunde und Geburtshilfe (Schwerpunkt Frauenheilkunde) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 23 Apr 2020 09:38 |
| Last Modified: | 23 Apr 2020 09:38 |
| URI: | https://pred.uni-regensburg.de/id/eprint/17006 |
Actions (login required)
 |
View Item |
